Optimization of cisplatin for the treatment of hormone dependent tumoral diseases Part 1: Use of steroidal ligands

被引：86

作者：

Gust, Ronald ^{[1
]}

Beck, Wolfgang ^{[2
]}

Jaouen, Gerard ^{[3
]}

Schoenenberger, Helmut ^{[4
]}

机构：

[1] Free Univ Berlin, Inst Pharm, D-14195 Berlin, Germany

[2] Univ Munich, Dept Chem & Biochem, D-81377 Munich, Germany

[3] Ecole Natl Super Chim Paris, F-75231 Paris 05, France

[4] Univ Regensburg, Inst Pharm, D-93053 Regensburg, Germany

来源：

COORDINATION CHEMISTRY REVIEWS | 2009年 / 253卷 / 21-22期

关键词：

Platinum complexes; Steroidal carrier ligands; Drug design; Mode of action; ESTROGEN-RECEPTOR MODULATORS; BIOLOGICALLY IMPORTANT LIGANDS; MXT-M-3,2 BREAST-CANCER; PROSPECTIVE RANDOMIZED-TRIAL; IMMUNE-RESPONSE MODIFIER; PROSTATE-CANCER; PLATINUM(II) COMPLEXES; ANTITUMOR-ACTIVITY; METAL-COMPLEXES; ESTER)PLATINUM(II) CHLORIDE;

D O I：

10.1016/j.ccr.2009.02.025

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

Platinum complexes such as cisplatin and carboplatin are metal based drugs, which are widely used in cancer chemotherapy. However, in the current therapy of hormone-dependent breast and prostate cancer they are not established. This might be the result of intrinsic and acquired resistance of the tumors during the therapy. Therefore, several attempts were done to design platinum complexes to address these tumors. Steroidal and non-steroidal drugs were modified for the coordination to platinum. The mode of action implies a binding to the estrogen receptor, a selective accumulation in the tumor cells and a specific binding to DNA. In part 1 of this review article we describe the use of steroidal ligands to optimize cisplatin for the treatment of hormone dependent tumoral diseases. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：2742 / 2759

页数：18

共 186 条

[1] METAL-COMPLEXES WITH BIOLOGICALLY IMPORTANT LIGANDS .62. PLATINUM(II) COMPLEXES OF 3-(2-AMINOETHOXY)ESTRONE AND 3-(2-AMINOETHOXY) ESTRADIOL [J].

ALTMAN, J ;

CASTRILLO, T ;

BECK, W ;

BERNHARDT, G ;

SCHONENBERGER, H .

INORGANIC CHEMISTRY, 1991, 30 (21) :4085-4088

[2] SYNTHESES AND AFFINITIES OF NOVEL ORGANOMETALLIC-LABELED ESTRADIOL DERIVATIVES - A STRUCTURE AFFINITY RELATIONSHIP [J].

AMOURI, H ;

VESSIERES, A ;

VICHARD, D ;

TOP, S ;

GRUSELLE, M ;

JAOUEN, G .

JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (17) :3130-3135

[3]

[Anonymous], 1967, Surg Gynecol Obstet, V124, P1011

[4] The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site [J].

Anstead, GM ;

Carlson, KE ;

Katzenellenbogen, JA .

STEROIDS, 1997, 62 (03) :268-303

[5]

BAILAR JC, 1970, CANCER, V26, P257, DOI 10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO

[6]

2-9

[7] Smoldering and polarized inflammation in the initiation and promotion of malignant disease [J].

Balkwill, F ;

Charles, KA ;

Mantovani, A .

CANCER CELL, 2005, 7 (03) :211-217

[8] Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes [J].

Barnes, KR ;

Kutikov, A ;

Lippard, SJ .

CHEMISTRY & BIOLOGY, 2004, 11 (04) :557-564

[9]

BARNES KR, 2002, 224 ACS NAT M BOST A, P110

[10]

BECK W, 1982, CHEM BER-RECL, V115, P2256, DOI 10.1002/cber.19821150621

← 1 2 3 4 5 6 7 8 9 10 →